⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388285 | 1.00 | — | — | |
| SCHEMBL736581 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL15366591 | 0.97 | — | — | |
| Bromide SCHEMBL2831090 | 0.97 | — | — | |
| SCHEMBL14086792 | 0.85 | — | — | |
| SCHEMBL12717639 | 0.85 | — | — | |
| SCHEMBL772391 | 0.85 | — | — | |
| SCHEMBL21230458 | 0.83 | KDM4E (0.35) | — | |
| SCHEMBL12716924 | 0.83 | HSD11B1 (0.33) | — | |
| SCHEMBL81186 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015864-A1 | CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230112012-A1 | FAP INHIBITOR | UNIVERSITAT HEIDELBERG (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-10822342-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| US-20190169198-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| US-10221180-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-05 | — | — | US | disclosed |
| US-20170334915-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20090036421-A1 | Pyrrole Derivative or Salt Thereof | ASTELLAS PHARMA INC (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036421-A1 | Pyrrole Derivative or Salt Thereof | ASTELLAS PHARMA INC (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1988075-A1 | PYRROLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1988076-A1 | AMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| EP-1891951-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |